 Optinose OPTN, a pharmaceutical company focused on patients treated by ear, nose and throat ENT and allergy specialists, today reported financial results for the quarter ended March 31, 2020, and provided operational updates. While large COVID-19 related reductions in patient flow through physician offices negatively influence the entire new prescription market, we are pleased with the comparative resilience of XHANCE during this period. During the pandemic, while not meeting our pre-crisis expectations, XHANCE has shown an increase in prescription volume. 